Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine

Journal of Acquired Immune Deficiency Syndromes

Volumn 38, Issue 2, 2005, Pages 147-155

  Shlay, Judith C ^a   Visnegarwala, Fehmida ^b   Bartsch, Glenn ^c   Wang, Jack ^d   Peng, Grace ^c   El Sadr, Wafaa M ^d   Gibert, Cynthia ^e   Kotler, Donald ^d   Grunfeld, Carl ^f   Raghavan, Subhasree ^d  

^a DENVER PUBLIC HEALTH   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d Columbia Univ Coll of Phys/Surgs ^*  (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adverse effects; Body composition; HIV; Lipoatrophy; Nucleoside reverse transcriptase inhibitor; Prospective; Randomized controlled trial

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THYMIDINE DERIVATIVE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; VIRUS RNA;

ADULT; ANTHROPOMETRY; ARTICLE; BODY CELL MASS; BODY COMPOSITION; BODY FAT; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPEDANCE; INSULIN RESISTANCE; LIPOATROPHY; LIPOHYPERTROPHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SKINFOLD THICKNESS; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTI-HIV AGENTS; BODY COMPOSITION; DIDANOSINE; DIDEOXYNUCLEOSIDES; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN; INSULIN RESISTANCE; LAMIVUDINE; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STAVUDINE;

EID: 19944431796     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000143599.64234.15     Document Type: Article

References (58)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy and insulin resistance due to HIV protease inhibitors. AIDS. 1998;12:F51-F58.
2. Miller KD, Jones E, Jack A, et al. Visceral abdominal-fat accumulation associated with the use of indinavir. Lancet. 1998;351:871-875.
3. Lo JC, Mulligan K, Tai VW, et al. "Buffalo hump" in men with HIV infection. Lancet. 1998;351:867-870.
4. Dube MP. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis. 2000;31:1467-1475.
5. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1 patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592-598.
6. Dube MP, Zackin R, Tebas P, et al. Prospective study of regional body composition in antiretroviral-naive subjects randomized to receive zidovudine + lamivudine or didanosine + stavudine combined with nelfinavir, efavirenz, or both: A5005s, a substudy of ACTG 384. Paper presented at: 4th International Workshop on Adverse Drug Reactions and Lipodsytrophy in HIV; September 22-25, 2002; San Diego, CA.
7. Purnell J, Zambon A, Knopp R, et al. Effect of ritonavir on lipids and postheparin lipase activities in normal subjects. AIDS. 2000;14:51-57.
8. Noor M, Lo J, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS. 2001;15:11-15.
9. Kakuda TN, Brundage R, Anderson P, et al. Nucleoside reverse transcriptase inhibitor-associated mitochondrial toxicity as an etiology for lipodsytrophy. AIDS. 1999;13:2311-2312.
10. Brinkman K, Smeitink J, Fomijn J, et al. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is key factor in the pathogenesis of antiretroviral therapy-related lipodsytrophy. Lancet. 1999;354:1112-1115.
11. Nolan D, Mallal S. Thymidine analogue-sparing highly active antiretroviral therapy (HAART). J HIV Ther. 2003;8:2-6.
12. Carr A, Workman C, Smith D, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002;288:207-215.
13. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001;15:1389-1398.
14. Bogner JR, Vielhauer V, Beckmann R, et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr. 2001;27:237-244.
15. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluation by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPCO study. AIDS. 2000;14:37-49.
16. Bernasconi E, Boubaker K, Junghans C, et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2002;31:50-55.
17. Mallon PWG, Miller J, Cooper D, et al. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS. 2003;17:971-979.
18. Mallal SA, John M, Moore C, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14:1309-1316.
19. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS. 2002;16:2447-2454.
20. Lichtenstein KA, Delaney K, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr. 2003;32:48-56.
21. Galli M, Ridolfo A, Fulvio A, et al. Body habitus changes and metabolic alterations in protease inhibitor naive HIV-1 infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2002;29:21-31.
22. Heath KV, Hogg R, Chan K, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS. 2001;15:231-239.
23. Nolan D, James J, McKinnon E, et al. Effect of stavudine, zidovudine and HIV protease inhibitor therapy on subcutaneous leg fat wasting in HIV-infected males: a longitudinal study. Antivir Ther. 2002;7:L18.
24. Jemsek J, Arathoon E, Ariotti M, et al. Atazanavir and efavirenz have similar effects on body fat distribution in antiretroviral-naive patients when combined with fixed-dose zidovudine and lamivudine: 48 week results from the metabolic substudy of BMS A1424-034. Antivir Ther. 2003;8:L15.
25. Podzamcer D, Ferrer E, Sanchez P, et al. Toxicity and efficacy of 3TC/EFV associated with stavudine or abacavir in antiretroviral-naive patients: 48-week results of a randomized open and multicenter trial (ABCDE Study). Paper presented at: 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2003; San Francisco, CA.
26. Gallant J, Staszewski S, Pozniak A, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
27. Martin A, Smith D, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX extension study. AIDS. 2004;18:1029-1036.
28. John M, McKinnon E, James I, et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr. 2003;33:29-33.
29. Moyle G, Baldwin B, Landroudi B, et al. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr. 2003;33:22-28.
30. Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1-19.
31. Wang J, Bartsch G, Raghavan S, et al. Reliability of body composition and skinfold measurements by observers trained in groups. IJBCR. 2004;2:31-36.
32. Lohman TG, Roche A, Martorell R. Anthropometric Standard Reference Manual. Champaign, IL: Human Kinectics; 1988.
33. Kotler DP, Burastero S, Wang J, et al. Prediction of body cell mass, fat-free mass and total body water with bioelectrical bioimpedance analysis: effects of race, gender and disease. Am J Clin Nutr. 1996;64:489-497.
34. Wang J, Thorton J, Kolesnik S, et al. Anthropometry in body composition: an overview. Ann NY Acad Sci. 2000;904:317-326.
35. Durnin J, Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr. 1974;32:77-97.
36. Wang J, Thorton J, Russell M, et al. Asians have lower body mass index (BMI) but higher percent body fat than do whites: comparisons of anthropometric measurements. Am J Clin Nutr. 1994;60:23-28.
37. Friedewald WT, Levy R, Fredrickson D. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
38. Yeni-Komshian H, Carantoni M, Abbasi F, et al. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care. 2000;23:171-175.
39. Mathews DR, Hosker J, Rudenski A, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
40. Laird NM, Ware J. Random-effects models for longitudinal data. Biometrics. 1982;38:963-974.
41. Blanco F, Garcia-Benayas T, Jose de la Cruz J, et al. First-line therapy and mitochondrial damage: different nucleosides, different findings. HIV Clin Trials. 2003;4:11-19.
42. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659-1667.
43. Walli R, Herfort O, Michl G, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS. 1998;12:F167-F173.
44. Mulligan K, Grunfeld C, Tai V, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000;23:35-43.
45. Cossarizza A, Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS. 2004;18:137-151.
46. Cote H, Brumme Z, Craib K, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med. 2002;346:811-820.
47. Montaner J, Cote H, Harris M, et al. Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;34(Suppl 1):S85-S90.
48. Walker UA, Bäuerle J, Laguno M, et al. Antiretroviral therapy with didanosine, stavudine and zalcitabine is associated with depletion of mitochondrial function. Antivir Ther. 2003;8:L15.
49. Moyle G, Datta D, Mandalia S, et al. Hyperlactatemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS. 2002;16:1341-1349.
50. Kotler DP, Rosenbaum K, Wang J, et al. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr. 1999;20:228-237.
51. National Cholesterol Education Program Expert Panel on Detection. Evaluation, and Treatment of the High Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adults Treatment Panel III). JAMA. 2001;285:2486-2497.
52. Fontas E, van Leth F, Sabin C, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189:1056-1074.
53. Gervasoni C, Ridolfo A, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1999;13:465-472.
54. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
55. Mazess RB, Barden H, Bisek J, et al. Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr. 1990;51:1106-1112.
56. Wang J, Kotler D, Russell M, et al. Body-fat measurement in patients with acquired immunodeficiency syndrome: which method should be used? Am J Clin Nutr. 1992;56:963-967.
57. Knox T, Zafonte-Sanders M, Fields-Gardner C, et al. Assessment of nutritional status, body composition, and human immunodeficiency virus-associated morphologic changes. Clin Infect Dis. 2003;36(Suppl 2):S63-S68.
58. He Q, Wang J, Engelson E, et al. Ability of an anthropometric model to track changes in subcutaneous adipose tissue area. FASEB J. 2002;16:A1024-A1025.